Skip to main content

Bio-Techne Obtains Reimbursement Contract With Humana for Exosome Diagnostics Prostate Biopsy Test

NEW YORK ─ Bio-Techne on Monday announced that Humana, a Medicare Advantage provider, has awarded a contract effective April 1 for coverage of its ExoDx Prostate (EPI) test for men performed at its Exosome Diagnostics laboratory.

Minneapolis, Minnesota-based Bio-Techne noted that Humana serves an estimated 20 million patients in the US.

Bio-Techne's EPI is a urine-based, genomic test that helps inform decisions about a prostate biopsy. The firm noted that its EPI test is covered by Medicare and several commercial payors. In 2020, it received a 10-year unlimited General Services Administration (GSA) award and was included in the National Comprehensive Cancer Network (NCCN) Guidelines for Early Detection of Prostate Cancer in men, for both initial and repeat biopsy, the firm said.

Its Exosome Diagnostics business performs the test in its laboratory located in Waltham, Massachusetts, which is CLIA-, ISO-, and New York state-certified and CAP-accredited.

"This coverage decision will expand access to this test, enabling additional men to make more informed decisions on whether to defer or proceed with a prostate biopsy," Chuck Kummeth, president and CEO of Bio-Techne, said in a statement. He added that the benefits of the test are increasingly resonating with both patients and payors.